Celladon Corporation Announces Presentation of First-in-Human Gene Transfer toTreat Heart Failure at the 12th Annual Meeting of the

Celladon Corporation Announces Presentation of First-in-Human Gene Transfer toTreat Heart Failure at the 12th Annual Meeting of the American Society of GeneTherapyPhase 1/2 Calcium Upregulation by Percutaneous Administration (CUPID) DataHighlight Safety Profile and Biological Effects of SERCA2a Enzyme ReplacementSAN DIEGO, May 26 /PRNewswire/ -- Celladon Corporation today announced thatresults from its genetically targeted enzyme replacement therapy for advancedheart failure, including Phase 1/2 data of MYDICAR(R) (AAV1/SERCA2a), will bepresented by Krisztina M. Zsebo, PhD, President and CEO, Celladon Corporationand Howard Dittrich, MD, Cardiologist at University of California, San DiegoSchool of Medicine, in a Scientific Symposium on Thursday, May 28 at the 2009American Society of Gene Therapy Annual Meeting, San Diego Convention Center."A key underpinning of heart failure is the depletion of SERCA2a enzyme inheart muscle cells, which results in abnormal intracellular calcium cyclingand poor contractility," said Zsebo. "Our research shows that recombinantadeno-associated viral vectors (AAV) are ideal for restoring SERCA2a enzymeproduction by means of cardiac muscle gene transfer. The path of investigationfor MYDICAR(R) (AAV1/SERCA2a), from rodent studies to the ongoing Phase IIclinical trial, has yielded valuable insights for the entire gene therapyfield, dispelling many myths and revealing strategies to enhance vector uptakein humans with numerous applications."While conventional drug therapies have improved survival of patients withcongestive heart failure, the disease progresses relentlessly, resulting inmore than 300,000 deaths each year, 6.5 million annual hospital days and anestimated $35 billion in direct and indirect healthcare expenditures. Recentadvances in understanding the molecular basis of myocardial dysfunction,together with the evolution of safe and efficient gene transfer technology,have placed heart failure within reach of gene-based therapy. A Phase 1/2clinical trial of dose escalation of MYDICAR administered directly to heartcells with minimally invasive cardiac catheterization is currently underway.This clinical study represents the first-in-human trial of enzyme replacementtherapy in heart failure using AAV and has demonstrated acceptable safety andproduced quantitative evidence of biological activity across a number ofparameters important for assessing heart failure.

Celladon is testing thehypotheses that restoring SERCA2a enzyme production will improve ventricularfunction in patients with advanced heart failure. About CelladonCelladon Corporation, based in La Jolla, California, was launched in October2004 as a privately held biotechnology company founded with the goal ofbecoming the leader in developing molecular therapies for the treatment ofheart failure. The company's products target the key enzyme deficiency inadvanced heart failure, SERCA2a, which regulates calcium cycling andcontractility in heart muscle cells. Celladon's first product candidate,MYDICAR, delivers the gene for the SERCA2a enzyme. MYDICAR is currently beingtested in Phase 1 and 2 clinical trials. Celladon is also developingtraditional small molecule activators of SERCA2a for the treatment of heartfailure.To learn more about Celladon, visit Celladon's website at CorporationStacie D. Byars, Mobile, +1-206-660-2588, , for CelladonCorporation.

SAN DIEGO, May 26 /PRNewswire-FirstCall/ -- Frontera Investment, Inc. Our goal is to have these stores profitable by December 2009.On May 18, 2009, Frontera opened its ninth store in Perris, California.Thisstore is located inside an ARCO ampm and is the Company's second full serviceembedded store.Frontera has two additional stores in the pipeline which willbe staged to open over the next few months as funding is obtained to financethe acquisition and working capital needs of each new store.The Hispanic market is currently estimated at 40 million consumers, over halfdo not use any form of banking service.About 35 percent of the total UShouseholds are un-banked or use alternative financial services companies. Frontera currently operates seven stores in California.Forward-Looking Statements:Such forward-looking statements are subject to a number of risks, assumptionsand uncertainties that could cause the Company's actual results to differmaterially from those projected in such forward-looking statements.Theserisks, assumptions and uncertainties include the ability to complete expansionwithin currently estimated time frames and budgets; the ability to competeeffectively in a rapidly evolving and price competitive marketplace; abilityto raise capital to support its growth strategy; changes in business strategy;and the successful integration of newly acquired businesses SOURCEFrontera Investment, Inc.Allan C. Youngberg, CFO of Frontera Investment, Inc., +1-858-549-7061,. Maryland's Place in Space: Exploring the Universe in Your Own Backyard at theBaltimore Convention CenterGREENBELT, Md., May 26 /PRNewswire-USNewswire/ -- Maryland's revolutionarywork in space and technology will be featured at the Baltimore ConventionCenter during a free, family event on Saturday, May 30 from 10 a.m.

to 4 p.m.EDT.(Logo: http:// )NASA's Goddard Space Flight Center in Greenbelt, Md. and the Johns HopkinsUniversity Applied Physics Laboratory (APL) in Laurel, Md. are hosting thisunprecedented showcase that will have over 100 imaginative, hands-on exhibits,NASA astronauts, mind-blowing multimedia presentations, thrilling roboticscompetitions, and much more.NASA Astronaut, Ricky Arnold, born and raised in Maryland, will be a specialguest at the expo. As mission specialist for NASA's latest mission to theInternational Space Station, STS-119, Arnold accumulated 12 hours and 34minutes of EVA during 2 spacewalks. During STS-119, Arnold and the rest of thecrew on space shuttle Discovery traveled 202 orbits and 5.3 million miles in12 days, 19 hours and 29 minutes.Highlighted activities at Maryland's Place in Space include a specialappearance by Sid the Science Kid (Maryland Public Television / PBSKids); makeyour own wing ring glider with NASA Astronauts, Special InteractivePresentation by Wall-E, a special performance & demonstration by Stormin' BobSwanson, "The Singing Weatherman;" and an Informative Science Cafe withScientists and Engineers.Throughout the 20,000 square feet of space of the Baltimore Convention Center,there will be over 100 exhibits and activities.